- The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, alongside existing investors Bioqube Ventures, Korys and Novo Holdings
- Funds will take first development candidate COM002 into the clinic, advance a second program into IND-enabling development and expand the BiCE™ pipeline
- Michael Rosenzweig (AbbVie Ventures), Charlotte Kremers (M Ventures) and Lenny Van Steenhuyse (Ackermans & van Haaren) join the Board of Directors
COPENHAGEN, Denmark, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, today announced the completion of a $60 million (€54 million) seed financing round to advance its pipeline of complement-powered immune engagers toward the clinic. The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, and existing investors Bioqube Ventures, Korys and Novo Holdings.
Proceeds from the financing will support the completion of IND-enabling activities and IND filing for COM002, Commit’s first development candidate, which was announced last week. COM002 is a dual-targeting Bispecific Complement Engager (BiCE™) molecule designed for targeted immune cell depletion, developed for patients with cancer and autoimmune disease. Additionally, the financing will advance a second program into IND-enabling development and expand Commit’s BiCE™ pipeline.
“Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy,” said Dr. Thomas L. F. Montgomery Andresen, CEO of Commit Biologics.
He added: “Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team.”
Charlotte Kremers, Principal at M Ventures, said: “Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.”
Lenny Van Steenhuyse, Investment Manager at Ackermans & van Haaren, added: “We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realize the full potential of the BiCE™ platform.”
For more information, please contact:
Optimum Strategic Communications
Nick Bastin, Stephen Adams, Aoife Minihan
Tel: +44 (0) 204 566 8543
Email: commit@optimumcomms.com
About the BiCE™ platform
Commit’s proprietary BiCE™ platform turns IgG antibodies into complement-powered immune engagers. BiCE™ antibodies are designed to recruit the complement protein C1q to induce rapid and selective elimination of targeted diseased cells through a T cell-independent mechanism. The platform taps into one of nature’s most ancient defense mechanisms, while retaining the properties of a conventional IgG antibody.
About Commit Biologics
Commit Biologics is developing complement-powered immune engagers, a new class of immunotherapies for autoimmune disease, oncology and beyond. Founded as a spin-out from Aarhus University, a long-standing internationally recognized hub for complement research, Commit is today based in Copenhagen and Aarhus. The company is backed by Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. www.commitbio.com